Wright J K, Smith A J, Cawston T E, Hazleman B L
Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, UK.
Agents Actions. 1989 Nov;28(3-4):279-82. doi: 10.1007/BF01967415.
The ability of the anabolic steroid, stanozolol, to stimulate procollagenase production by human synovial and skin fibroblasts was examined in an in vitro assay system. Stanozolol is used therapeutically to treat a variety of connective tissue and vascular disorders and its clinical effects suggest that it can modulate connective tissue breakdown. The results showed that stanozolol was capable, in a dose dependent manner, of significantly stimulating procollagenase production by skin fibroblasts. However, in three synovial fibroblast lines no evidence was found of increased collagenase production following treatment with stanozolol; although the synovial fibroblasts secreted significantly increased amounts of procollagenase in response to IL-1. These results may shed some light on the mechanism of action in vivo of stanozolol in the treatment of connective tissue disorders.
在体外分析系统中检测了合成代谢类固醇司坦唑醇刺激人滑膜成纤维细胞和皮肤成纤维细胞产生原胶原酶的能力。司坦唑醇在治疗上用于治疗多种结缔组织和血管疾病,其临床效果表明它可以调节结缔组织的分解。结果显示,司坦唑醇能够以剂量依赖的方式显著刺激皮肤成纤维细胞产生原胶原酶。然而,在用司坦唑醇处理的三个滑膜成纤维细胞系中,未发现胶原酶产生增加的证据;尽管滑膜成纤维细胞对白细胞介素-1有反应,分泌的原胶原酶量显著增加。这些结果可能有助于阐明司坦唑醇在治疗结缔组织疾病中的体内作用机制。